Better Together: Collaborating to Simplify Complexities in Drug Development

The global healthcare environment continues to grow and evolve rapidly, and biopharmaceutical companies are under immense pressure to continue to innovate efficient and cost-effective solutions, as well as to streamline their products’ path to market. It is imperative that contract development manufacturing organizations (CDMO) also find solutions that align with that same sense of urgency without compromising quality or volume.

As two leading CDMOS, Vetter and Rentschler Biopharma are both committed to simplifying processes, reducing complexity, and optimizing time-to-market while continuing to deliver on our high-quality standards and sustainably support our clients’ needs. As such, we are pleased to announce a strategic collaboration aimed at achieving long-term value for our clients through the alignment of manufacturing approaches. This alliance will combine complementary skills and experience along the biopharmaceutical value chain, allowing us to leverage our individual strengths, industry expertise, and core competencies to collaboratively enhance our respective services, enabling clients to bring their products to patients faster.

Supporting Clients through a Collaborative, Complementary Partnership

It is important for businesses to sometimes think outside the box. Pursuing future-oriented and innovative ideas is part of both of our companies’ DNA. Combining Vetter’s expertise in aseptic fill and finish and secondary packaging with Rentschler Biopharma’s expertise in drug substance manufacturing, including bioprocess development and active pharmaceutical ingredient (API) production, represents a tremendous opportunity. Sharing knowledge and best practices as well as filling knowledge gaps to gain market foresight can positively impact our respective clients and the patients they serve.

Our companies have been working together to actively exchange ideas and protocols early on. The opportunities that will be explored throughout this collaboration include optimization of interfaces and communications at an early stage; alignment of client questionnaires to get early access to product facts and timelines; simplification of structures, procedures, and activities; streamlining of processes from early clinical development through delivery of commercial products; and sharing early visibility into manufacturing requirements. We will both continue to independently support new and existing clients while exploring opportunities for cooperative integration of approaches. 

There are important synergies between our business portfolios that will provide valuable market insight. Combining our experience enables us to deliver new pathways for the efficient development of biopharmaceuticals and to address challenges faced by companies across the industry. This synergistic endeavor will be further validated in the form of pilot client projects with joint teams from each company.

As two leading CDMOS, Vetter and Rentschler Biopharma are both committed to simplifying processes, reducing complexity, and optimizing time-to-market while continuing to deliver on our high-quality standards and sustainably support our clients’ needs.

About Vetter

Headquartered in Ravensburg, Germany, Vetter is a global leading CDMO with production facilities in Germany and the United States. Currently employing 5,000 individuals worldwide, the company has long-term experience in supporting biotechnology and pharmaceutical customers both large and small. Vetter services range from early-stage development support, including clinical manufacturing, to commercial supply and numerous packaging solutions for vials, syringes, and cartridges. As a leading solution provider, Vetter appreciates its responsibility to support the needs of its customers by developing devices that contribute to increased patient safety, convenience, and enhanced compliance. 

About Rentschler Biopharma SE 

Rentschler Biopharma is a global leading CDMO focused exclusively on client projects. From its headquarters in Laupheim, Germany, and its site in Milford, Massachusetts, Rentschler Biopharma offers process development and manufacturing of biopharmaceuticals as well as related consulting activities, including project management and regulatory support. Rentschler Biopharma’s high quality is proven by its long-standing experience and excellence as a solution partner for its clients. In order to offer best-in-class formulation development along the biopharmaceutical value chain, the company has entered into a strategic alliance with Leukocare AG. Rentschler Biopharma is a family-owned company with about 1,000 employees. 

Peter Soelkner

Peter has been Managing Director since 2008. Before he held positions at Sartorius AG and Sartorius North America Inc., in R&D, marketing, key account management and general management. From 2003 to 2007 he managed Vetter’s key account program and global supply chain. He left the company for a year to serve as Vice President Global Key Account Management at Sartorius Stedim Biotech, before returning to Vetter. He graduated in chemical engineering from the University of Dortmund, Germany and holds an MBA from Columbia University, NY.